Form 4: AngioDynamics SVP Laura Piccinini Reports Acquisition of Stock and Derivative Securities

Laura Piccinini, SVP International at AngioDynamics, reports the acquisition of common stock, performance rights, and stock options.

Summary

• Laura Piccinini, SVP International at AngioDynamics, filed a Form 4 detailing changes in beneficial ownership.
• On July 17, 2024, Piccinini acquired 21,971 shares of AngioDynamics common stock, representing restricted stock units.
• These restricted stock units vest in four equal annual installments starting July 17, 2025.
• Piccinini also acquired 30,428 performance rights, each representing a contingent right to receive one share of common stock.
• The number of shares earned from performance rights will be based on total shareholder return relative to a peer group over a three-year period, with potential adjustments.
• Additionally, Piccinini acquired 29,863 non-qualified stock options with an exercise price of $7.40, vesting in four equal annual installments starting July 17, 2025.
• Following these transactions, Piccinini directly owns 41,064 shares of common stock and 29,863 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock and derivative securities by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for the restricted stock units and stock options incentivize long-term commitment from the executive.

Future Outlook

The vesting schedules for the restricted stock units and stock options suggest an expectation of continued employment and positive performance over the next four years. The performance rights payout is contingent on the company's total shareholder return relative to its peers over a three-year period.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common forms of executive compensation in the medical device industry, used to align management's interests with those of shareholders.
• Vesting schedules of four years are typical for these types of equity grants.
• Performance-based equity awards, such as the performance rights granted to Piccinini, are also increasingly common, linking executive compensation to specific company performance metrics.

Stakeholder Impact

• The transactions reported in the Form 4 filing have a limited direct impact on stakeholders.
• However, they provide transparency into executive compensation and alignment with shareholder interests.

Key Dates